文献速递角膜与眼表疾病

基于纳米平台跨上皮核黄素/UV-A角膜交联诱导人角膜生物力学强化

Biomechanical Strengthening of the Human Cornea Induced by Nanoplatform-Based Transepithelial Riboflavin/UV-A Corneal Cross-Linking.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究用原子力显微镜评估基于纳米平台的跨上皮核黄素/UV-A角膜交联协议对人供体巩角膜组织的生物力学硬化效果。四个标本接受该跨上皮交联,结果与四个常规交联标本及四个未处理标本比较。跨上皮交联后最前部基质杨氏模量为未处理对照的2.5倍,常规交联为1.7倍,两者间差异显著。

要点

  • 跨上皮纳米平台交联后最前部基质杨氏模量为未处理对照的2.5倍(P < 0.001)。
  • 常规交联后最前部基质杨氏模量为未处理对照的1.7倍(P < 0.001)。
  • 两种交联方案间最前部基质硬度差异显著(P < 0.001)。

核心结论

  • 基于纳米技术的跨上皮核黄素/UV-A角膜交联能有效提高人角膜最前部基质的生物力学强度。

研究设计与样本

  • 研究使用12例眼库供体人巩角膜组织,用商用原子力显微镜以力谱模式检测。
  • 4例接受跨上皮交联:使用含0.1%核黄素、可生物降解的2-羟丙基-β-环糊精聚合物纳米颗粒及增强剂(氨丁三醇和乙二胺四乙酸)的低渗溶液,并用10 mW/cm2装置UV-A照射9分钟。
  • 治疗后用Amoils刷去除角膜上皮,用原子力显微镜定量最前部基质的杨氏模量随扫描速率的变化。
  • 结果与4例接受常规核黄素/UV-A角膜交联的标本及4例未处理标本比较。

主要发现

  • 跨上皮交联后最前部基质平均杨氏模量为未处理对照的2.5倍(P < 0.001)。
  • 常规交联后最前部基质平均杨氏模量为未处理对照的1.7倍(P < 0.001)。
  • 两种角膜交联方案间最前部基质硬度差异显著(P < 0.001)。
  • 压痕深度在交联后降低:未处理样本平均2.4 ± 0.3 μm,跨上皮交联后平均1.2 ± 0.1 μm,常规交联后平均1.8 ± 0.1 μm。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to investigate the biomechanical stiffening effect induced by nanoplatform-based transepithelial riboflavin/UV-A cross-linking protocol using atomic force microscopy (AFM). METHODS: Twelve eye bank donor human sclerocorneal tissues were investigated using a commercial atomic force microscope operated in force spectroscopy mode. Four specimens underwent transepithelial corneal cross-linking using a hypotonic solution of 0.1% riboflavin with biodegradable polymeric nanoparticles of 2-hydroxypropyl-β-cyclodextrin plus enhancers (trometamol and ethylenediaminetetraacetic acid) and UV-A irradiation with a 10 mW/cm2 device for 9 minutes. After treatment, the corneal epithelium was removed using the Amoils brush, and the Young's modulus of the most anterior stroma was quantified as a function of scan rate by AFM. The results were compared with those collected from four specimens that underwent conventional riboflavin/UV-A corneal cross-linking and four untreated specimens. RESULTS: The average Young's modulus of the most anterior stroma after the nanoplatform-based transepithelial and conventional riboflavin/UV-A corneal cross-linking treatments was 2.5 times (P < 0.001) and 1.7 times (P < 0.001) greater than untreated controls respectively. The anterior stromal stiffness was significantly different between the two corneal cross-linking procedures (P < 0.001). The indentation depth decreased after corneal cross-linking treatments, ranging from an average of 2.4 ± 0.3 μm in untreated samples to an average of 1.2 ± 0.1 μm and 1.8 ± 0.1 μm after nanoplatform-based transepithelial and conventional cross-linking, respectively. CONCLUSIONS: The present nanotechnology-based transepithelial riboflavin/UV-A corneal cross-linking was effective to improve the biomechanical strength of the most anterior stroma of the human cornea.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Labate C, Lombardo M, Lombardo G, et al. Biomechanical Strengthening of the Human Cornea Induced by Nanoplatform-Based Transepithelial Riboflavin/UV-A Corneal Cross-Linking. Invest Ophthalmol Vis Sci. 2017. PMID: 28114577. doi:10.1167/iovs.16-20813

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。